Ariad opts for genome profiling to advance NSCLC product
This article was originally published in Clinica
Executive Summary
In a bold move Massachusetts-based Ariad Pharmaceuticals is partnering with Foundation Medicine, a molecular information company, to use genomic profiling to identify the optimal patient population for its investigational non-small cell lung cancer drug AP26113. Even though genomic profiling has been available for some time, few companies have used it to develop their regulatory approval submissions.